Neiges is developing a drug discovery engine for Crohn's disease using its proprietary immunocompetent-transmural intestinal organoid (MiniGut). MiniGut can scalably attain clinically-relevant functional readouts and high-resolution omics data on transmural pathological processes, uniquely overcoming the lack of a human translational model in this space.
What is the problem?
A major challenge in Crohn's disease drug development stems from the lack of preclinical models that can recapitulate the immunological and transmural pathobiology seen in patients. Specifically, fibrosis of the intestinal wall affects two million patients with Crohn's disease worldwide resulting in high morbidity. To date, no drugs are approved for this indication.
What is their solution?
Neiges is building a drug discovery engine for Crohn's disease using its proprietary immunocompetent-transmural intestinal organoid (MiniGut), which the company produces from patient-derived induced pluripotent stem cells. By leveraging machine learning models to resolve unique multimodal data—such as clinically relevant functional readouts and high-resolution omics data—Neiges aims to discover and develop novel therapeutics for Crohn's disease and fibrosis.
